Please use this identifier to cite or link to this item:
Title: Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
Authors: CANCADO, Guilherme Grossi LopesCOUTO, Claudia AlvesGUEDES, Laura VilarBRAGA, Michelle HarrizTERRABUIO, Debora Raquel BeneditaCANCADO, Eduardo Luiz RachidFERRAZ, Maria Lucia GomesVILLELA-NOGUEIRA, Cristiane AlvesNARDELLI, Mateus JorgeFARIA, Luciana CostaOLIVEIRA, Elze Maria Gomes deROTMAN, VivianMAZO, Daniel Ferraz de CamposBORGES, Valeria Ferreira de Almeida eMENDES, Liliana Sampaio CostaCODES, LianaPESSOA, Mario GuimaraesSIGNORELLI, Izabelle VenturiniLEVY, CynthiaBITTENCOURT, Paulo Lisboa
Citation: FRONTIERS IN PHARMACOLOGY, v.12, article ID 818089, 6p, 2022
Abstract: Aim: Up to 40% of patients with primary biliary cholangitis (PBC) will have a suboptimal biochemical response to ursodeoxycholic acid (UDCA), which can be improved by the addition of fibrates. This exploratory study aims to evaluate the long-term real-life biochemical response of different fibrates, including ciprofibrate, in subjects with UDCA-unresponsive PBC.Methods: The Brazilian Cholestasis Study Group multicenter database was reviewed to assess the response rates to UDCA plus fibrates in patients with UDCA-unresponsive PBC 1 and 2 years after treatment initiation by different validated criteria.Results: In total, 27 patients (100% women, mean age 48.9 +/- 9.2 years) with PBC were included. Overall response rates to fibrates by each validated criterion varied from 39 to 60% and 39-76% at 12 and 24 months after treatment combination, respectively. Combination therapy resulted in a significant decrease in ALT and ALP only after 2 years, while GGT significantly improved in the first year of treatment. Treatment response rates at 1 and 2 years appear to be comparable between ciprofibrate and bezafibrate using all available criteria.Conclusion: Our findings endorse the efficacy of fibrate add-on treatment in PBC patients with suboptimal response to UDCA. Ciprofibrate appears to be at least as effective as bezafibrate and should be assessed in large clinical trials as a possibly new, cheaper, and promising option for treatment of UDCA-unresponsive PBC patients.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MGT
Departamento de Gastroenterologia - FM/MGT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/06
LIM/06 - Laboratório de Imunopatologia da Esquistossomose e outras Parasitoses

Files in This Item:
File Description SizeFormat 
art_CANCADO_Fibrates_for_the_Treatment_of_Primary_Biliary_Cholangitis_2022.PDFpublishedVersion (English)708.14 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.